Podcasts about Medivation

Welcome, Med Tech Gurus! You are in for a fantastic episode today as we sit down with Samina Bari, a strategic advisor with over 30 years of experience in business strategy, corporate governance, and operations. Samina has navigated high-stakes environments, working on transformative acquisitions worth over $40 billion, including major deals like Medivation by Pfizer and Ikaria by Mallinckrodt. In this episode, Samina shares her expertise on managing corporate crises, including cybersecurity breaches, hostile takeovers, and the challenges of scaling companies in complex industries. She also discusses her passion for innovation in healthcare, her advocacy for women-led ventures, and the importance of maintaining a clear "North Star" in business. Get ready to learn from a true leader in risk management and strategic advising. This episode is packed with valuable insights for anyone in the medtech or biotech fields.

As much of the world's focus this past year has been on making progress in fighting off the COVID-19 pandemic, some remained focused on other raging epidemics that existed prior to the emergence of COVID-19 and continue to worsen over time. For Rohan Palekar, CEO of 89bio, a clinical-stage biopharmaceutical start-up, the raging epidemic is non-alcoholic steatohepatitis (NASH) and he discusses how they haven't allowed the pandemic or the failures of other NASH treatments to hinder their progress of developing a solution for NASH. He talks about what's on the horizon for 89bio, including plans for continuing the development of their lead candidate, BIO89-100 with the initiation of a Phase 2b trial for the treatment of (NASH). #89bio #NASH Rohan Palekar is a seasoned C-suite executive with over 25 years of experience in the biopharmaceutical industry. Most recently, Rohan was the president and CEO of Avanir Pharmaceuticals (2015-2017) after serving as its EVP-Chief Operations Officer (2015). Rohan joined Avanir in 2012 as SVP-Chief Commercial Officer (CCO) and as part of the senior leadership team led the organization through a dynamic growth phase. Avanir was acquired by Otsuka Pharmaceuticals in 2015. Prior to Avanir, Rohan served as the CCO of Medivation (2008-2011), where he oversaw commercial, medical affairs, CMC & manufacturing, and public relations. Earlier in his career, Rohan spent 16 years at Johnson & Johnson in various senior commercial and strategic management roles, including worldwide VP of immunology and VP of sales and marketing at Centocor. Rohan holds an MBA from the Amos Tuck School of Business Administration at Dartmouth College and a BA/BS in law and accounting from the University of Bombay.

We are continuing our conversation with Dr. Paula O'Connor and delving into the role of pharma in access to medicine and clinical trials. Dr. O'Connor goes over the safety measures in place to keep patients safe throughout a trial and how clinical trials can give access to novel drugs to patients who may not otherwise be able to afford them.About Dr. Paula O'ConnorDr. O'Connor is a hematologist oncologist with over 15 years of experience in biotech and drug development leading Clinical Development, Medical Affairs functions, managing people and teams, while helping to bring multiple products to the market.  Most recently, Dr. O'Connor led the US Medical Affairs function at Oncopeptides, Inc., helping them to commercialize their first product, a peptide drug conjugate. Earlier in her career, Dr. O'Connor led programs for novel biologics (Rituxan, Avastin), small molecules (Tarceva, Nexavar, rociletinib, Rubraca, and Talzenna), and biosimilars (Udenyca).Paula served as the Executive Vice President of Clinical Development at Coherus Biosciences; the Global Development Lead for Talzenna at Medivation through its acquisition by Pfizer; the Medical Affairs Lead for Rubraca and rociletinib at Clovis Oncology; the Joint Global Development Lead for Nexavar and Global Development Lead for Oprozomib at Onyx Pharmaceuticals through its acquisition by Amgen; and in roles of increasing responsibility at Genentech, Inc. through its acquisition by Roche.Paula obtained her medical degree from Stanford University; did her Medical residency at Massachusetts General Hospital, where she was the first African American Chief Resident in Internal Medicine; and did her Hematology-Oncology fellowship at the MGH/BWH/DFCI combined program.Outside of work, Paula is a parent, a tennis fan, and the owner of 2 burmese cats.--New Episodes every Tuesday, available wherever you get your podcasts! Rate and Subscribe! Also, join us for our live streams on Facebook and Youtube!Sign Up for our newsletter here or at 3BlackDocs.com  A special thanks to our sponsor, Oncopeptides. Oncopeptides is a rapidly growing biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company is science driven and committed to bringing innovation to patients with an unmet medical need and improving patient lives. Oncopeptides is committed to the diversity of Multiple Myeloma patients and doing their part to eradicate health disparities in African American patients. Learn more about Oncopeptides at https://www.oncopeptides.com/en Join the Conversation! Follow us on social media!3 Black Docsfacebook.com/3blackdocstwitter.com/3blackdocsinstagram.com/3blackdocsYouTube.com/3blackdocsDr. Karen Winkfieldfacebook.com/drwinkfieldtwitter.com/drwinkfieldinstagram.com/drwinkfieldDr. Zanetta Lamarfacebook.com/drzanettainstagram.com/drzanetta

We are so excited for this next episode with our special guest, Dr. Paula O'Connor! We talk about finding your path in medicine and all of the many opportunities there are to follow your passions within the medical field. Dr. O'Connor gave us so many gems development of career and development of self.About Dr. Paula O'ConnorDr. O'Connor is a hematologist oncologist with over 15 years of experience in biotech and drug development leading Clinical Development, Medical Affairs functions, managing people and teams, while helping to bring multiple products to the market.  Most recently, Dr. O'Connor led the US Medical Affairs function at Oncopeptides, Inc., helping them to commercialize their first product, a peptide drug conjugate. Earlier in her career, Dr. O'Connor led programs for novel biologics (Rituxan, Avastin), small molecules (Tarceva, Nexavar, rociletinib, Rubraca, and Talzenna), and biosimilars (Udenyca).Paula served as the Executive Vice President of Clinical Development at Coherus Biosciences; the Global Development Lead for Talzenna at Medivation through its acquisition by Pfizer; the Medical Affairs Lead for Rubraca and rociletinib at Clovis Oncology; the Joint Global Development Lead for Nexavar and Global Development Lead for Oprozomib at Onyx Pharmaceuticals through its acquisition by Amgen; and in roles of increasing responsibility at Genentech, Inc. through its acquisition by Roche.Paula obtained her medical degree from Stanford University; did her Medical residency at Massachusetts General Hospital, where she was the first African American Chief Resident in Internal Medicine; and did her Hematology-Oncology fellowship at the MGH/BWH/DFCI combined program.Outside of work, Paula is a parent, a tennis fan, and the owner of 2 burmese cats.--New Episodes every Tuesday, available wherever you get your podcasts! Rate and Subscribe! Also, join us for our live streams on Facebook and Youtube!Sign Up for our newsletter here or at 3BlackDocs.com  A special thanks to our sponsor, Oncopeptides. Oncopeptides is a rapidly growing biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company is science driven and committed to bringing innovation to patients with an unmet medical need and improving patient lives. Oncopeptides is committed to the diversity of Multiple Myeloma patients and doing their part to eradicate health disparities in African American patients. Learn more about Oncopeptides at https://www.oncopeptides.com/en Join the Conversation! Follow us on social media!3 Black Docsfacebook.com/3blackdocstwitter.com/3blackdocsinstagram.com/3blackdocsYouTube.com/3blackdocsDr. Karen Winkfieldfacebook.com/drwinkfieldtwitter.com/drwinkfieldinstagram.com/drwinkfieldDr. Zanetta Lamarfacebook.com/drzanettainstagram.com/drzanetta

Andy Protter, PhD. joined Auransa in January 2017 as Chief Scientific Officer with 35 years of pharmaceutical industry research and development experience. At Auransa, Dr. Protter has led preclinical R&D which uses AI technology to discover novel drug candidates. Auransa’s lead project for hepatocellular carcinoma has completed all IND-supporting preclinical safety studies. Prior to joining Auransa, Dr. Protter was a Vice President at Medivation where he was responsible for preclinical pharmacology and toxicology of Enzalutamide, a prostate cancer drug that was approved by the FDA. Prior to Medivation, Dr. Protter worked at Scios, a biotechnology company where he also lead preclinical development. Dr. Protter initiated the Natrecor development program and was responsible for all preclinical activities. Natrecor was approved by the FDA for acute decompensated congestive heart failure. In addition Dr. Protter led preclinical efforts selecting a p38 MAP kinase inhibitor drug candidate that was tested in patients with rheumatoid arthritis and surgical pain. In 2004 Johnson and Johnson awarded Dr. Protter the Johnson Medal for his work on Natrecor. Trained as a biochemist at the State University of New York at Stony Brook, Dr. Protter led the first successful cloning of apolipoprotein B, the primary protein on LDL. He has participated in work described in over 84 published papers, 4 book chapters and 28 patents. When not doing science, Andy enjoys hobbies including biking, skiing, sailing, photography and reading.

Dr. Lynn Seeley is the CEO of Myovant Sciences. She is an endocrinologist with over 20 years of drug development and biopharmaceutical company leadership experience. Prior to joining Myovant, she served as Chief Medical Officer of Medivation for 10 years where she led the development of XTANDI® (enzalutamide) for the treatment of metastatic castration-resistant prostate cancer. Today Lynn and Donnica are taking a break from talking about the pandemic to go back to the basics of the ladies' room:  period talk. Women don't talk about their periods enough so often women are silently suffering from really harsh period pains. Lynn encourages women to be more open about their periods so that they can know their period better. So they open up and share their own period horror stories so you can feel ready to share your own!

– Pfizer leva Medivation e conversa pra levar AstraZeneca – CEO da Uber descarta comprar Lyft – Pokemon da Nintendo chegou no limite – Empire State Building vendido para o Qatar – Rusoro Mining vai recuperar grana da expropriação da Venezuela – Berkshire do Warren Buffet comprou 15% dá… Você pode assinar o Feed do […] The post Papo de Dividendo #24: BKS – PFE – UBER – NTDOY – ESRT – RMLFF appeared first on Viver de Dividendos.

An EpiPen pricing debacle, an unexpected FDA rejection, and a sticker-shock inspiring M&A deal led to wild moves in Mylan N.V., Portola Pharmaceuticals, and Medivation this week.  

Today in FirstWord:

As the number of media outlets -- and reporters -- covering deals has risen, so the news flow has boomed, creating what at times feels like an information overload. Looking for an example? Sanofi's attempted takeover of Medivation has yielded no fewer than 1,500 news stories since Bloomberg’s first report back in March -- an average of 10 stories a day for five months. Here, Jeff McCracken, Bloomberg's executive editor of deals, discusses the right and wrong ways to cover a fast-moving M&A story.

(Bloomberg) -- Taking Stock with Kathleen Hays and Pimm Fox. u0010 u0010GUEST: u0010Cynthia Koons u0010Health Care Reporter u0010Bloomberg Editorial u0010on Pfizer beating out rivals to buy biopharmaceutical company, Medivation, and its blockbuster cancer drug for $14 billion.

Today in FirstWord:

Market Analyst, Clive Ramathibela Asian shares slipping this morning, Pharmaceutical company, Pfizer Inc in deals to acquire cancer drug company, Medivation for close to 14 billion dollar and what's next for Brazil after the Rio olympics

Healthcare analysts Arthur Wong and Adam Dibe chat about some recent pharma developments – Amgen's biosimilar on Humira, Big Pharma's interest in biopharmaceutical company, Medivation, Inc., and an investor question on specialty pharma company Endo International PLC.

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

(Bloomberg) -- Taking Stock with Kathleen Hays and Pimm Fox. GUEST: Sasha Damouni, First Word health care reporter for Bloomberg, on the latest news at the UBS health care conference in NYC: Valeant, Allergan and Medivation. Broadcasting live from the BNY Mellon Asset Servicing Conference in Tuscon, Arizona.

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

1) Longitudinal study of normal cognition in Parkinson disease and 2) Topic of the month: Neurology Today: Recent Publications. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Matthew Barrett interviews Dr. Daniel Weintraub about his paper on studying normal cognition in Parkinson disease. Dr. Ted Burns is interviewing Mike Avery for our “What's Trending” feature of the week about things happening in the Beltway of interest to neurologists. In the next part of the podcast Dr. Ted Burns interviews Dr. Steve Ringel about a Neurology Today story on the topic of uptick in cases of narcolepsy. The participants had nothing to disclose except Drs. Barrett, Weintraub, Burns and Ringel.Dr. Barrett received research support from the Virginia Center of Alzheimer´s and Related Diseases Research Award Fund.Dr. Weintraub serves as an editorial board member of Movement Disorders Journal and Journal of Parkinson's Disease; serves on the scientific advisory boards for Pfizer, Inc, Teva Pharmaceuticals Industries Ltd., Avanir Pharmaceuticals, Merck Serono, Lundbeck Inc. UCB, Bristol-Myers Squibb, Novartis, Clintrex, LLC, Theravance Biopharma, Medivation, Inc. Non-profit-CHDI, ADCS; receives licensing fees from the University of Pennsylvania for licensing of Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease; receives research support from Novartis, Michael J. Fox Foundation and the NIH; gave expert testimony for defense in 2012-2014 in two lawsuits related to impulse control disorders in Parkinson disease.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Ringel serves as editor of Neurology Today.

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

1) Depressive symptoms and risk of dementia and 2) Early history of the AAN. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. David Geldmacher interviews Dr. Jane Saczynski about her paper on depressive symptoms and risk of dementia. In the next segment, Dr. Jennifer Fugate is reading our e-Pearl of the week about wrong way eyes. In the next part of the podcast Dr. Ted Burns interviews Dr. Robert Joynt on the early history of the AAN for our Lesson of the Week. The participants had nothing to disclose except Drs. Fugate, Burns and Joynt. Dr. Geldmacher serves on editorial board of Brain Injury, has received speaker honoraria from Danville Regional Medical Center, Georgetown Medical School, University of Rochester, Cleveland Clinic, Kaiser Permanante and Academy for Healthcare Education, receives research support from Elan Corporation [PI], Eisai Inc. [PI], Medivation, Inc. [PI], Janssen [PI] and Novartis [PI].Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Burns receives a stipend as Podcast Editor for Neurology®, and performs EMG studies in his neuromuscular practice (30% effort).Dr. Joynt receives a stipend as Newsletter Editor for Neurology® and royalties from Archives of Neurology for published work.

This Podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Burns interview Dr. Stephen Salloway about his paper on using bapineuzumab in mild to moderate Alzheimer disease. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about the Heidenhain variant of Creutzfeldt Jakob disease. The podcast concludes where Dr. Beau Bruce interviews Dr. Brian Weinshenker for the Lesson of the Week (disease of the month) on triptans. The participants had nothing to disclose except Drs. Burns & Salloway. Dr. Burns serves on the Neurology Podcast Committee.Dr. Salloway serves on scientific advisory boards for Myriad Genetics, Inc, Elan Corporation, Sanofi-aventis, Eisai Inc., and Pfizer; serves on the editorial board of the Journal of Neuropsychiatry and Clinical Neurosciences; receives royalties from American Psychiatric Press Inc and Humana Press; received speaker honoraria from Eisai Inc., Pfizer, Novartis, Forest Laboratories, Inc. and Elan Corporation; serves as a consultant to Merck Serono and Medivation-data safety committee; receives research support from Elan Corporation, Wyeth, Bristol-Myers Squibb, Alzheimers Disease Neuroimaging Initiative, Dominantly Inherited Alzheimers Network, Aging Brain: DTI, Subcortical Ischemia and Behavior and NIH [NIA 1 R03 AGO23916-01A1]; receives funding from The Norman and Rosalie Fain Family Foundation.